Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Authors:
- Murat EmreMEMurat Emre
- Magda TsolakiMagda Tsolaki
- Ubaldo BonuccelliUBUbaldo Bonuccelli
- Alain DestéeADAlain Destée
- Eduardo TolosaETEduardo Tolosa
- Alexandra KutzelniggAKAlexandra Kutzelnigg
- Andrés Ceballos-BaumannACAndrés Ceballos-Baumann
- Slobodan ZdravkovicSZSlobodan Zdravkovic
- Anna BladströmABAnna Bladström
- Roy JonesRJRoy Jones
- 1 October 2010
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 9 (10) , 969-977
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
- Novartis
This publication has 23 references indexed in Scilit:
- Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomographyJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Clinical diagnostic criteria for dementia associated with Parkinson's diseaseMovement Disorders, 2007
- Imaging β-amyloid burden in aging and dementiaNeurology, 2007
- DLB and PDD boundary issuesNeurology, 2007
- Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy BodiesThe Journal of Neuroscience, 2007
- A systematic review of prevalence studies of dementia in Parkinson's diseaseMovement Disorders, 2005
- Visual perception in Parkinson disease dementia and dementia with Lewy bodiesNeurology, 2004
- Rivastigmine for Dementia Associated with Parkinson's DiseaseNew England Journal of Medicine, 2004
- Risk of dementia in Parkinson’s diseaseNeurology, 2001
- Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international studyThe Lancet, 2000